Phaseline

Companies › RDC Clinical

RDC Clinical: clinical trials, targets and expected readouts

10 active drug programs in 47 registered trials: 17 Phase 2, 14 Phase 4, 13 Phase 3, 3 Phase 1; Other, Neurology, Psychiatry, Immunology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
life's Omega 1035DS
Microalgal-derived omega-3 (EPA/DHA) formulation
–Phase 4Optimal Absorption of Omega-3Apr 2027
life's Omega O3020DS
Microalgal-derived omega-3 (EPA/DHA) formulation
–Phase 4Optimal Absorption of Omega-3Apr 2027
Aquacelle® Omega 3
Omega-3 fatty acid supplement (EPA and DHA)
–Phase 4Healthy VolunteerSep 2027
Cholecalciferol
Vitamin D receptor agonist
VDRPhase 4Healthy Volunteer; COVID-19; Bronchiectasis; Osteoarthritis …Sep 2027
Caffeine
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 4Exercise; Migraine; Healthy; Vibration Therapy …–
Testofen 300mg
Fenugreek seed extract (traditional herbal testosterone support)
–Phase 3Erectile Dysfunction–
Lavender Oil (CPO Lavender oil)
Herbal supplement; mechanism in sleep/stress not fully established
–Phase 2Sleep Disorder (Disorder)Feb 2027
Oleoylethanolamide (Trpti)
Endocannabinoid-like compound; TRPV1 and PPAR-alpha agonist with appetite regulation and s
TRPV1, PPARAPhase 2Sleep Disorder (Disorder); Healthy VolunteersFeb 2027
Palmitoylethanolamide (PEA)
Endocannabinoid-like lipid signaling molecule; acts as agonist at TRPV1 and PPARα receptor
TRPV1, PPARAPhase 2Sleep Disorder (Disorder); Healthy; Persistent Postural Perceptual DizzinessFeb 2027
Levagen+ (palmitoylethanolamide, PEA)
Lipid signaling molecule; TRPV1 antagonist and PPARδ agonist with anti-inflammatory and ne
TRPV1, PPARDPhase 2Diabetic Peripheral Neuropathy–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04482673CholecalciferolPhase 4COVID-19Infectious diseaseDec 2022
NCT04482673CholecalciferolPhase 4COVID-19Infectious diseaseDec 2022
NCT07022496CaffeinePhase 4MigraineNeurologyJul 2025
NCT04775381CholecalciferolPhase 3HypocalcemiaMetabolic and endocrineDec 2025
NCT07469852CaffeinePhase 1CaffeineOtherMar 2026
NCT07028528Levagen+ (palmitoylethanolamide, PEA)Phase 2Diabetic Peripheral NeuropathyNeurologyMay 2026
NCT05232279Testofen 300mgPhase 3Erectile DysfunctionGenitourinaryJul 2026
NCT05232279Testofen 300mgPhase 3Erectile DysfunctionGenitourinaryJul 2026
NCT02178410CholecalciferolPhase 3Cardiovascular DiseaseCardiovascularOct 2026
NCT07434752CaffeinePhase 4ExerciseOtherOct 2026
NCT04677816CholecalciferolPhase 2Triple Negative Breast CancerOncologyDec 2026
NCT06327152CaffeinePhase 2Apnea of PrematurityOtherDec 2026
NCT01419730CholecalciferolPhase 2Bone Metabolism BiomarkersOtherDec 2026
NCT06551337CholecalciferolPhase 4BronchiectasisRespiratoryDec 2026
NCT03613116CholecalciferolPhase 2Vitamin D DeficiencyMetabolic and endocrineDec 2026
NCT06763172CaffeinePhase 4HealthyOtherDec 2026
NCT07315516Palmitoylethanolamide (PEA)Phase 2Sleep Disorder (Disorder)PsychiatryFeb 2027
NCT07315516Lavender Oil (CPO Lavender oil)Phase 2Sleep Disorder (Disorder)PsychiatryFeb 2027
NCT07315516Oleoylethanolamide (Trpti)Phase 2Sleep Disorder (Disorder)PsychiatryFeb 2027
NCT07921810CaffeinePhase 4Vibration TherapyOtherMar 2027
NCT03516968CholecalciferolPhase 3Obesity, ChildhoodMetabolic and endocrineMar 2027
NCT03516968CholecalciferolPhase 3Obesity, ChildhoodMetabolic and endocrineMar 2027
NCT07457723Oleoylethanolamide (Trpti)Phase 2Healthy VolunteersOtherMar 2027
NCT06629103life's Omega 1035DSPhase 4Optimal Absorption of Omega-3OtherApr 2027
NCT06629103life's Omega O3020DSPhase 4Optimal Absorption of Omega-3OtherApr 2027
NCT06741358Palmitoylethanolamide (PEA)Phase 4Persistent Postural Perceptual DizzinessImmunologyMay 2027
NCT06508099CholecalciferolPhase 2Acute Lymphoblastic LeukemiaOncologyMay 2027
NCT07006714CholecalciferolPhase 4OsteoarthritisImmunologyJul 2027
NCT03188796CholecalciferolPhase 3Critical IllnessInfectious diseaseJul 2027
NCT00856947CholecalciferolPhase 1AsthmaRespiratoryJul 2027
NCT07177157CholecalciferolPhase 1Ulcerative Colitis (UC)ImmunologyJul 2027
NCT06717867Palmitoylethanolamide (PEA)Phase 2HealthyOtherAug 2027
NCT07791797Aquacelle® Omega 3Phase 4Healthy VolunteerOtherSep 2027
NCT07791797CholecalciferolPhase 4Healthy VolunteerOtherSep 2027
NCT04094688CholecalciferolPhase 3Colorectal AdenocarcinomaOncologyDec 2027
NCT04570085CaffeinePhase 3Alzheimer DiseaseNeurologyDec 2027
NCT03768492CaffeinePhase 2Carcinoma BreastOncologyDec 2027
NCT06757244CholecalciferolPhase 2Pancreas NeoplasmsOncologyFeb 2028
NCT05174611CholecalciferolPhase 2Anterior Cruciate Ligament InjuriesOtherMar 2028
NCT02112734CholecalciferolPhase 4Food AllergyImmunologyApr 2028
NCT05043116CholecalciferolPhase 2Asthma in ChildrenRespiratoryOct 2028
NCT07269457CholecalciferolPhase 2Traumatic Brain Injury (TBI) PatientsNeurologyDec 2028
NCT07647198CholecalciferolPhase 2Uterine Fibroids (Leiomyoma)OncologyAug 2029
NCT07448974CholecalciferolPhase 3PrediabetesMetabolic and endocrineMar 2030
NCT04442412CholecalciferolPhase 3Diffuse Large B-Cell LymphomaOncologySep 2030
NCT01169259CholecalciferolPhase 3CancerOncologyMar 2031
NCT06570889CholecalciferolPhase 3AsthmaRespiratoryMar 2033

Targets

TRPV1 (3) PPARA (2) VDR (1) ADORA1 (1) ADORA2B (1) ADORA3 (1) ADORA2A (1) PPARD (1)

Companies with the same targets

Valenta Pharm JSC Heron Therapeutics Ipsen Kowa Company Zydus Therapeutics Inventiva Pharma OPKO Health Gilead Sciences Can-Fite BioPharma

Companies built like this

Mylan Pharmaceuticals Mesoblast ROKIT Healthcare MaaT Pharma Photozig

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.